Normal and malignant megakaryopoiesis

Qiang Wen; Benjamin Goldenson; John D. Crispino

doi:10.1017/S1462399411002043

Normal and malignant megakaryopoiesis

Published online by Cambridge University Press: 21 October 2011

Qiang Wen ,

Benjamin Goldenson and

John D. Crispino

Show author details

Qiang Wen: Affiliation:
Division of Hematology/Oncology, Northwestern University, Chicago, IL, USA
Benjamin Goldenson: Affiliation:
Division of Hematology/Oncology, Northwestern University, Chicago, IL, USA
John D. Crispino*: Affiliation:
Division of Hematology/Oncology, Northwestern University, Chicago, IL, USA
*: *Corresponding author: John D. Crispino, Division of Hematology/Oncology, Northwestern University, 303 East Superior Street, Lurie 5-113, Chicago, IL 60611, USA. E-mail: j-crispino@northwestern.edu

Article contents

Abstract
References

Get access

Rights & Permissions

Abstract

Megakaryopoiesis is the process by which bone marrow progenitor cells develop into mature megakaryocytes (MKs), which in turn produce platelets required for normal haemostasis. Over the past decade, molecular mechanisms that contribute to MK development and differentiation have begun to be elucidated. In this review, we provide an overview of megakaryopoiesis and summarise the latest developments in this field. Specially, we focus on polyploidisation, a unique form of the cell cycle that allows MKs to increase their DNA content, and the genes that regulate this process. In addition, because MKs have an important role in the pathogenesis of acute megakaryocytic leukaemia and a subset of myeloproliferative neoplasms, including essential thrombocythemia and primary myelofibrosis, we discuss the biology and genetics of these disorders. We anticipate that an increased understanding of normal MK differentiation will provide new insights into novel therapeutic approaches that will directly benefit patients.

Type: Review Article
Information: Expert Reviews in Molecular Medicine , Volume 13 , March 2011 , e32

DOI: https://doi.org/10.1017/S1462399411002043 [Opens in a new window]
Copyright: Copyright © Cambridge University Press 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Lichtman, M.A. et al. (2011) Williams Manual of Hematology (8th edn), McGraw-Hill, New YorkGoogle Scholar

2Kanz, L. et al. (1982) Identification of human megakaryocytes derived from pure megakaryocytic colonies (CFU-M), megakaryocytic-erythroid colonies (CFU-M/E), and mixed hemopoietic colonies (CFU-GEMM) by antibodies against platelet associated antigens. Blut 45, 267-274CrossRef Google Scholar PubMed

3Nakahata, T., Gross, A.J. and Ogawa, M. (1982) A stochastic model of self-renewal and commitment to differentiation of the primitive hemopoietic stem cells in culture. Journal of Cellular Physiology 113, 455-458CrossRef Google Scholar PubMed

4Akashi, K. et al. (2000) A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 404, 193-197CrossRef Google Scholar PubMed

5Reya, T. et al. (2001) Stem cells, cancer, and cancer stem cells. Nature 414, 105-111CrossRef Google Scholar PubMed

6Ogawa, M. (1993) Differentiation and proliferation of hematopoietic stem cells. Blood 81, 2844-2853CrossRef Google Scholar PubMed

7Kondo, M., Weissman, I.L. and Akashi, K. (1997) Identification of clonogenic common lymphoid progenitors in mouse bone marrow. Cell 91, 661-672CrossRef Google Scholar PubMed

8Debili, N. et al. (1996) Characterization of a bipotent erythro-megakaryocytic progenitor in human bone marrow. Blood 88, 1284-1296CrossRef Google Scholar PubMed

9Papayannopoulou, T. et al. (1996) Insights into the cellular mechanisms of erythropoietin–thrombopoietin synergy. Experimental Hematology 24, 660-669Google Scholar PubMed

10Adolfsson, J. et al. (2001) Upregulation of Flt3 expression within the bone marrow Lin(−)Sca1(+)c-kit(+) stem cell compartment is accompanied by loss of self-renewal capacity. Immunity 15, 659-669CrossRef Google Scholar PubMed

11Adolfsson, J. et al. (2005) Identification of Flt3+ lympho-myeloid stem cells lacking erythro-megakaryocytic potential a revised road map for adult blood lineage commitment. Cell 121, 295-306CrossRef Google Scholar PubMed

12Forsberg, E.C. et al. (2006) New evidence supporting megakaryocyte-erythrocyte potential of flk2/flt3+ multipotent hematopoietic progenitors. Cell 126, 415-426CrossRef Google Scholar PubMed

13Nakorn, T.N., Miyamoto, T. and Weissman, I.L. (2003) Characterization of mouse clonogenic megakaryocyte progenitors. Proceedings of the National Academy of Sciences of the United States of America 100, 205-210CrossRef Google Scholar PubMed

14Tober, J. et al. (2007) The megakaryocyte lineage originates from hemangioblast precursors and is an integral component both of primitive and of definitive hematopoiesis. Blood 109, 1433-1441CrossRef Google Scholar PubMed

15Tober, J., McGrath, K.E. and Palis, J. (2008) Primitive erythropoiesis and megakaryopoiesis in the yolk sac are independent of c-myb. Blood 111, 2636-2639CrossRef Google Scholar PubMed

16Xie, X. et al. (2003) Thrombopoietin promotes mixed lineage and megakaryocytic colony-forming cell growth but inhibits primitive and definitive erythropoiesis in cells isolated from early murine yolk sacs. Blood 101, 1329-1335CrossRef Google Scholar PubMed

17Vitrat, N. et al. (1998) Endomitosis of human megakaryocytes are due to abortive mitosis. Blood 91, 3711-3723CrossRef Google Scholar PubMed

18Harker, L.A. (1968) Kinetics of thrombopoiesis. Journal of Clinical Investigation 47, 458-465CrossRef Google Scholar PubMed

19Ebbe, S. et al. (1968) Megakaryocyte maturation rate in thrombocytopenic rats. Blood 32, 787-795CrossRef Google Scholar PubMed

20Lordier, L. et al. (2008) Megakaryocyte endomitosis is a failure of late cytokinesis related to defects in the contractile ring and Rho/Rock signaling. Blood 112, 3164-3174CrossRef Google Scholar PubMed

21Lordier, L. et al. (2010) Aurora B is dispensable for megakaryocyte polyploidization, but contributes to the endomitotic process. Blood 116, 2345-2355CrossRef Google Scholar

22Eliades, A., Papadantonakis, N. and Ravid, K. (2010) New roles for cyclin E in megakaryocytic polyploidization. Journal of Biological Chemistry 285, 18909-18917CrossRef Google Scholar PubMed

23Sun, S. et al. (2001) Overexpression of cyclin D1 moderately increases ploidy in megakaryocytes. Haematologica 86, 17-23Google Scholar PubMed

24Zimmet, J.M. et al. (1997) A role for cyclin D3 in the endomitotic cell cycle. Molecular and Cellular Biology 17, 7248-7259CrossRef Google Scholar PubMed

25Zimmet, J.M., Toselli, P. and Ravid, K. (1998) Cyclin D3 and megakaryocyte development: exploration of a transgenic phenotype. Stem Cells 16 (Suppl. 2), 97-106CrossRef Google Scholar PubMed

26Muntean, A.G. et al. (2007) Cyclin D-Cdk4 is regulated by GATA-1 and required for megakaryocyte growth and polyploidization. Blood 109, 5199-5207CrossRef Google Scholar PubMed

27Geng, Y. et al. (2003) Cyclin E ablation in the mouse. Cell 114, 431-443CrossRef Google Scholar PubMed

28Chagraoui, H. et al. (2011) SCL-mediated regulation of the cell-cycle regulator p21 is critical for murine megakaryopoiesis. Blood 118, 723-735CrossRef Google Scholar PubMed

29Gilles, L. et al. (2008) P19INK4D links endomitotic arrest and megakaryocyte maturation and is regulated by AML-1. Blood 111, 4081-4091CrossRef Google Scholar PubMed

30Ganem, N.J., Storchova, Z. and Pellman, D. (2007) Tetraploidy, aneuploidy and cancer. Current Opinion in Genetics and Development 17, 157-162CrossRef Google Scholar PubMed

31Ito, D. and Matsumoto, T. (2010) Molecular mechanisms and function of the spindle checkpoint, a guardian of the chromosome stability. Advances in Experimental Medicine and Biology 676, 15-26CrossRef Google Scholar PubMed

32Nakaya, T. et al. (2010) Critical role of Pcid2 in B cell survival through the regulation of MAD2 expression. Journal of Immunology 185, 5180-5187CrossRef Google Scholar

33Vernole, P. et al. (2009) TAp73alpha binds the kinetochore proteins Bub1 and Bub3 resulting in polyploidy. Cell Cycle 8, 421-429CrossRef Google Scholar PubMed

34Wang, Q. et al. (2004) BUBR1 deficiency results in abnormal megakaryopoiesis. Blood 103, 1278-1285CrossRef Google Scholar PubMed

35Ruchaud, S., Carmena, M. and Earnshaw, W.C. (2007) Chromosomal passengers: conducting cell division. Nature Reviews. Molecular Cell Biology 8, 798-812CrossRef Google Scholar PubMed

36Gurbuxani, S. et al. (2005) Differential requirements for survivin in hematopoietic cell development. Proceedings of the National Academy of Sciences of the United States of America 102, 11480-11485CrossRef Google Scholar PubMed

37Wen, Q. et al. (2009) Survivin is not required for the endomitotic cell cycle of megakaryocytes. Blood 114, 153-156CrossRef Google Scholar

38Geddis, A.E. and Kaushansky, K. (2004) Megakaryocytes express functional Aurora-B kinase in endomitosis. Blood 104, 1017-1024CrossRef Google Scholar PubMed

39Zhang, Y. et al. (2004) Aberrant quantity and localization of Aurora-B/AIM-1 and survivin during megakaryocyte polyploidization and the consequences of Aurora-B/AIM-1-deregulated expression. Blood 103, 3717-3726CrossRef Google Scholar PubMed

40Barr, F.A. and Gruneberg, U. (2007) Cytokinesis: placing and making the final cut. Cell 131, 847-860CrossRef Google Scholar PubMed

41Burkard, M.E. et al. (2007) Chemical genetics reveals the requirement for Polo-like kinase 1 activity in positioning RhoA and triggering cytokinesis in human cells. Proceedings of the National Academy of Sciences of the United States of America 104, 4383-4388CrossRef Google Scholar PubMed

42Lowery, D.M. et al. (2007) Proteomic screen defines the Polo-box domain interactome and identifies Rock2 as a Plk1 substrate. EMBO Journal 26, 2262-2273CrossRef Google Scholar PubMed

43Petronczki, M. et al. (2007) Polo-like kinase 1 triggers the initiation of cytokinesis in human cells by promoting recruitment of the RhoGEF Ect2 to the central spindle. Developmental Cell 12, 713-725CrossRef Google Scholar

44Yagi, M. and Roth, G.J. (2006) Megakaryocyte polyploidization is associated with decreased expression of polo-like kinase (PLK). Journal of Thrombosis and Haemostasis 4, 2028-2034CrossRef Google Scholar PubMed

45Cantor, A.B. and Orkin, S.H. (2002) Transcriptional regulation of erythropoiesis: an affair involving multiple partners. Oncogene 21, 3368-3376CrossRef Google Scholar PubMed

46Shivdasani, R.A. et al. (1997) A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. EMBO Journal 16, 3965-3973CrossRef Google Scholar PubMed

47Vyas, P. et al. (1999) Different sequence requirements for expression in erythroid and megakaryocytic cells within a regulatory element upstream of the GATA-1 gene. Development 126, 2799-2811CrossRef Google Scholar PubMed

48Tsang, A.P. et al. (1998) Failure of megakaryopoiesis and arrested erythropoiesis in mice lacking the GATA-1 transcriptional cofactor FOG. Genes and Development 12, 1176-1188CrossRef Google Scholar PubMed

49Chang, A.N. et al. (2002) GATA-factor dependence of the multitype zinc-finger protein FOG-1 for its essential role in megakaryopoiesis. Proceedings of the National Academy of Sciences of the United States of America 99, 9237-9242CrossRef Google Scholar PubMed

50Crispino, J.D. (2005) GATA1 in normal and malignant hematopoiesis. Seminars in Cell and Developmental Biology 16, 137-147CrossRef Google Scholar PubMed

51Tubman, V.N. et al. (2007) X-linked gray platelet syndrome due to a GATA1 Arg216Gln mutation. Blood 109, 3297-3299CrossRef Google Scholar PubMed

52Phillips, J.D. et al. (2007) Congenital erythropoietic porphyria due to a mutation in GATA1: the first trans-acting mutation causative for a human porphyria. Blood 109, 2618-2621CrossRef Google Scholar PubMed

53Miccio, A. et al. (2010) NuRD mediates activating and repressive functions of GATA-1 and FOG-1 during blood development. EMBO Journal 29, 442-456CrossRef Google Scholar PubMed

54Gregory, G.D. et al. (2010) FOG1 requires NuRD to promote hematopoiesis and maintain lineage fidelity within the megakaryocytic-erythroid compartment. Blood 115, 2156-2166CrossRef Google Scholar PubMed

55Tracey, W.D. and Speck, N.A. (2000) Potential roles for RUNX1 and its orthologs in determining hematopoietic cell fate. Seminars in Cell and Developmental Biology 11, 337-342CrossRef Google Scholar PubMed

56Kundu, M. et al. (2002) Role of Cbfb in hematopoiesis and perturbations resulting from expression of the leukemogenic fusion gene Cbfb-MYH11. Blood 100, 2449-2456CrossRef Google Scholar PubMed

57Elagib, K.E. et al. (2003) RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation. Blood 101, 4333-4341CrossRef Google Scholar PubMed

58Lorsbach, R.B. et al. (2004) Role of RUNX1 in adult hematopoiesis: analysis of RUNX1-IRES-GFP knock-in mice reveals differential lineage expression. Blood 103, 2522-2529CrossRef Google Scholar PubMed

59Ichikawa, M. et al. (2004) AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nature Medicine 10, 299-304CrossRef Google Scholar

60Growney, J.D. et al. (2005) Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. Blood 106, 494-504CrossRef Google Scholar PubMed

61Putz, G. et al. (2006) AML1 deletion in adult mice causes splenomegaly and lymphomas. Oncogene 25, 929-939CrossRef Google Scholar PubMed

62Sun, W. and Downing, J.R. (2004) Haploinsufficiency of AML1 results in a decrease in the number of LTR-HSCs while simultaneously inducing an increase in more mature progenitors. Blood 104, 3565-3572CrossRef Google Scholar

63Nucifora, G. and Rowley, J.D. (1995) AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. Blood 86, 1-14CrossRef Google Scholar

64Song, W.J. et al. (1999) Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nature Genetics 23, 166-175CrossRef Google Scholar PubMed

65Peterson, L.F. and Zhang, D.E. (2004) The 8;21 translocation in leukemogenesis. Oncogene 23, 4255-4262CrossRef Google Scholar

66Hock, H. et al. (2004) Tel/Etv6 is an essential and selective regulator of adult hematopoietic stem cell survival. Genes and Development 18, 2336-2341CrossRef Google Scholar PubMed

67Hart, A. et al. (2000) Fli-1 is required for murine vascular and megakaryocytic development and is hemizygously deleted in patients with thrombocytopenia. Immunity 13, 167-177CrossRef Google Scholar PubMed

68Spyropoulos, D.D. et al. (2000) Hemorrhage, impaired hematopoiesis, and lethality in mouse embryos carrying a targeted disruption of the Fli1 transcription factor. Molecular and Cellular Biology 20, 5643-5652CrossRef Google Scholar PubMed

69Ano, S. et al. (2004) Erythroblast transformation by FLI-1 depends upon its specific DNA binding and transcriptional activation properties. Journal of Biological Chemistry 279, 2993-3002CrossRef Google Scholar PubMed

70Athanasiou, M. et al. (2000) FLI-1 is a suppressor of erythroid differentiation in human hematopoietic cells. Leukemia 14, 439-445CrossRef Google Scholar PubMed

71Pang, L. et al. (2006) Maturation stage-specific regulation of megakaryopoiesis by pointed-domain Ets proteins. Blood 108, 2198-2206CrossRef Google Scholar PubMed

72Stankiewicz, M.J. and Crispino, J.D. (2009) ETS2 and ERG promote megakaryopoiesis and synergize with alterations in GATA-1 to immortalize hematopoietic progenitor cells. Blood 113, 3337-3347CrossRef Google Scholar PubMed

73Salek-Ardakani, S. et al. (2009) ERG is a megakaryocytic oncogene. Cancer Research 69, 4665-4673CrossRef Google Scholar PubMed

74Hall, M.A. et al. (2003) The critical regulator of embryonic hematopoiesis, SCL, is vital in the adult for megakaryopoiesis, erythropoiesis, and lineage choice in CFU-S12. Proceedings of the National Academy of Sciences of the United States of America 100, 992-997CrossRef Google Scholar PubMed

75Tripic, T. et al. (2009) SCL and associated proteins distinguish active from repressive GATA transcription factor complexes. Blood 113, 2191-2201CrossRef Google Scholar PubMed

76Gekas, C. et al. (2009) Mef2C is a lineage-restricted target of Scl/Tal1 and regulates megakaryopoiesis and B-cell homeostasis. Blood 113, 3461-3471CrossRef Google Scholar PubMed

77Ma, Z. et al. (2001) Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia. Nature Genetics 28, 220-221CrossRef Google Scholar

78Halene, S. et al. (2010) Serum response factor is an essential transcription factor in megakaryocytic maturation. Blood 116, 1942-1950CrossRef Google Scholar PubMed

79Ragu, C. et al. (2010) The serum response factor (SRF)/megakaryocytic acute leukemia (MAL) network participates in megakaryocyte development. Leukemia 24, 1227-1230CrossRef Google Scholar PubMed

80Dameshek, W. (1951) Some speculations on the myeloproliferative syndromes. Blood 6, 372-375CrossRef Google Scholar PubMed

81Fialkow, P.J., Gartler, S.M. and Yoshida, A. (1967) Clonal origin of chronic myelocytic leukemia in man. Proceedings of the National Academy of Sciences of the United States of America 58, 1468-1471CrossRef Google Scholar PubMed

82Gilliland, D.G. et al. (1991) Clonality in myeloproliferative disorders: analysis by means of the polymerase chain reaction. Proceedings of the National Academy of Sciences of the United States of America 88, 6848-6852CrossRef Google Scholar PubMed

83Adamson, J.W. et al. (1976) Polycythemia vera: stem-cell and probable clonal origin of the disease. New England Journal of Medicine 295, 913-916CrossRef Google Scholar PubMed

84Tefferi, A. (2000) Myelofibrosis with myeloid metaplasia. New England Journal of Medicine 342, 1255-1265CrossRef Google Scholar PubMed

85Baxter, E.J. et al. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365, 1054-1061CrossRef Google Scholar PubMed

86James, C. et al. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434, 1144-1148CrossRef Google Scholar PubMed

87Kralovics, R. et al. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. New England Journal of Medicine 352, 1779-1790CrossRef Google Scholar PubMed

88Levine, R.L. et al. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7, 387-397CrossRef Google Scholar PubMed

89Saharinen, P., Takaluoma, K. and Silvennoinen, O. (2000) Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Molecular and Cellular Biology 20, 3387-3395CrossRef Google Scholar PubMed

90Ihle, J.N. and Gilliland, D.G. (2007) Jak2: normal function and role in hematopoietic disorders. Current Opinion in Genetics and Development 17, 8-14CrossRef Google Scholar PubMed

91Scott, L.M. et al. (2006) Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 108, 2435-2437CrossRef Google Scholar

92Scott, L.M. et al. (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. New England Journal of Medicine 356, 459-468CrossRef Google Scholar PubMed

93Wernig, G. et al. (2006) Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107, 4274-4281CrossRef Google Scholar

94Tiedt, R. et al. (2008) Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 111, 3931-3940CrossRef Google Scholar PubMed

95Lacout, C. et al. (2006) JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 108, 1652-1660CrossRef Google Scholar PubMed

96Huang, Z. et al. (2007) STAT1 promotes megakaryopoiesis downstream of GATA-1 in mice. Journal of Clinical Investigation 117, 3890-3899CrossRef Google Scholar PubMed

97Chen, E. et al. (2010) Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell 18, 524-535CrossRef Google Scholar PubMed

98Dawson, M.A. et al. (2009) JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature 461, 819-822CrossRef Google Scholar PubMed

99Griffiths, D.S. et al. (2011) LIF-independent JAK signalling to chromatin in embryonic stem cells uncovered from an adult stem cell disease. Nature Cell Biology 13, 13-21CrossRef Google Scholar PubMed

100Akada, H. et al. (2010) Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood 115, 3589-3597CrossRef Google Scholar PubMed

101Li, J. et al. (2010) JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood 116, 1528-1538CrossRef Google Scholar

102Marty, C. et al. (2010) Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. Blood 116, 783-787CrossRef Google Scholar PubMed

103Mullally, A. et al. (2010) Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 17, 584-596CrossRef Google Scholar PubMed

104Pikman, Y. et al. (2006) MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Medicine 3, e270CrossRef Google Scholar PubMed

105Chaligne, R. et al. (2008) New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition. Leukemia 22, 1557-1566CrossRef Google Scholar PubMed

106Pardanani, A.D. et al. (2006) MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 108, 3472-3476CrossRef Google Scholar PubMed

107Beer, P.A. et al. (2008) MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 112, 141-149CrossRef Google Scholar PubMed

108Ding, J. et al. (2004) Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood 103, 4198-4200CrossRef Google Scholar PubMed

109Vannucchi, A.M. et al. (2008) Characteristics and clinical correlates of MPL 515W > L/K mutation in essential thrombocythemia. Blood 112, 844-847CrossRef Google Scholar PubMed

110Guglielmelli, P. et al. (2007) Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. British Journal of Haematology 137, 244-247CrossRef Google Scholar PubMed

111Takaki, S. et al. (2002) Enhanced hematopoiesis by hematopoietic progenitor cells lacking intracellular adaptor protein, Lnk. Journal of Experimental Medicine 195, 151-160CrossRef Google Scholar PubMed

112Tong, W. and Lodish, H.F. (2004) Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis. Journal of Experimental Medicine 200, 569-580CrossRef Google Scholar PubMed

113Velazquez, L. et al. (2002) Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice. Journal of Experimental Medicine 195, 1599-1611CrossRef Google Scholar PubMed

114Lasho, T.L., Pardanani, A. and Tefferi, A. (2010) LNK mutations in JAK2 mutation-negative erythrocytosis. New England Journal of Medicine 363, 1189-1190CrossRef Google Scholar PubMed

115Oh, S.T. et al. (2010) Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 116, 988-992CrossRef Google Scholar PubMed

116Pardanani, A. et al. (2010) LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia 24, 1713-1718CrossRef Google Scholar PubMed

117Lasho, T.L. et al. (2011) Clonal hierarchy and allelic mutation segregation in a myelofibrosis patient with two distinct LNK mutations. Leukemia 25, 1056-8CrossRef Google Scholar

118Rudd, C.E. (2001) Lnk adaptor: novel negative regulator of B cell lymphopoiesis. Sci STKE 2001, pe1 85, 1-3Google Scholar

119Bersenev, A. et al. (2010) Lnk constrains myeloproliferative diseases in mice. Journal of Clinical Investigation 120, 2058-2069CrossRef Google Scholar PubMed

120Delhommeau, F. et al. (2009) Mutation in TET2 in myeloid cancers. New England Journal of Medicine 360, 2289-2301CrossRef Google Scholar PubMed

121Carbuccia, N. et al. (2009) Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 23, 2183-2186CrossRef Google Scholar PubMed

122Green, A. and Beer, P. (2010) Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. New England Journal of Medicine 362, 369-370CrossRef Google Scholar PubMed

123Tefferi, A. et al. (2010) IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 24, 1302-1309CrossRef Google Scholar PubMed

124Grand, F.H. et al. (2009) Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 113, 6182-6192CrossRef Google Scholar PubMed

125Jager, R. et al. (2010) Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. Leukemia 24, 1290-1298CrossRef Google Scholar PubMed

126Ernst, T. et al. (2010) Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nature Genetics 42, 722-726CrossRef Google Scholar PubMed

127Tefferi, A. and Vainchenker, W. (2011) Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. Journal of Clinical Oncology 29, 573-582CrossRef Google Scholar PubMed

128Verstovsek, S. (2010) Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis. Clinical Cancer Research 16, 1988-1996CrossRef Google Scholar PubMed

129Pardanani, A. et al. (2011) JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia 25, 218-225CrossRef Google Scholar

130Marubayashi, S. et al. (2010) HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. Journal of Clinical Investigation 120, 3578-3593CrossRef Google Scholar PubMed

131Wang, Y. et al. (2009) Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood 114, 5024-5033CrossRef Google Scholar PubMed

132Guglielmelli, P. et al. (2011) Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood 118, 2069-2076CrossRef Google Scholar

133Tallman, M.S. et al. (2000) Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience. Blood 96, 2405-2411Google Scholar PubMed

134Pagano, L. et al. (2002) Acute megakaryoblastic leukemia: experience of GIMEMA trials. Leukemia 16, 1622-1626CrossRef Google Scholar PubMed

135Barnard, D.R. et al. (2007) Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: report from the Children's Oncology Group. Pediatric Blood and Cancer 49, 17-22CrossRef Google Scholar PubMed

136Hasle, H. et al. (2008) Myeloid leukemia in children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML. Leukemia 22, 1428-1430CrossRef Google Scholar PubMed

137Langebrake, C., Creutzig, U. and Reinhardt, D. (2005) Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts. Klinische Padiatrie 217, 126-134CrossRef Google Scholar PubMed

138Creutzig, U. et al. (2005) AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia 19, 1355-1360CrossRef Google Scholar PubMed

139Rao, A. et al. (2006) Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. British Journal of Haematology 132, 576-583CrossRef Google Scholar PubMed

140Gamis, A.S. et al. (2003) Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891. Journal of Clinical Oncology 21, 3415-3422CrossRef Google Scholar

141Zwaan, C.M. et al. (2002) Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. Blood 99, 245-251CrossRef Google Scholar PubMed

142Gamis, A.S. (2005) Acute myeloid leukemia and Down syndrome evolution of modern therapy – -state of the art review. Pediatric Blood and Cancer 44, 13-20CrossRef Google Scholar PubMed

143Wickrema, A. and Crispino, J.D. (2007) Erythroid and megakaryocytic transformation. Oncogene 26, 6803-6815CrossRef Google Scholar PubMed

144Vyas, P. and Crispino, J.D. (2007) Molecular insights into Down syndrome-associated leukemia. Current Opinion in Pediatrics 19, 9-14CrossRef Google Scholar PubMed

145Hollanda, L.M. et al. (2006) An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis. Nature Genetics 38, 807-812CrossRef Google Scholar PubMed

146Li, Z. et al. (2005) Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nature Genetics 37, 613-619CrossRef Google Scholar PubMed

147Malinge, S., Izraeli, S. and Crispino, J.D. (2009) Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. Blood 113, 2619-2628CrossRef Google Scholar PubMed

148Walters, D.K. et al. (2006) Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 10, 65-75CrossRef Google Scholar PubMed

149Kiyoi, H. et al. (2007) JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults. Leukemia 21, 574-576CrossRef Google Scholar PubMed

150De Vita, S. et al. (2007) Loss-of-function JAK3 mutations in TMD and AMKL of Down syndrome. British Journal of Haematology 137, 337-341CrossRef Google Scholar PubMed

151Sato, T. et al. (2008) Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome. British Journal of Haematology 141, 681-688CrossRef Google Scholar PubMed

152Cornejo, M.G., Boggon, T.J. and Mercher, T. (2009) JAK3: a two-faced player in hematological disorders. International Journal of Biochemistry and Cell Biology 41, 2376-2379CrossRef Google Scholar PubMed

153Radtke, I. et al. (2009) Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America 106, 12944-12949CrossRef Google Scholar PubMed

154Leow, S. et al. (2011) FLT3 mutation and expression did not adversely affect clinical outcome of childhood acute leukaemia-a study of 531 Southeast Asian children by the Ma-Spore study group. Hematological Oncology doi: 10.1002/hon.987. [Epub ahead of print]CrossRef Google Scholar

155Klusmann, J.H. et al. (2010) Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis. Genes and Development 24, 1659-1672CrossRef Google Scholar PubMed

156Ge, Y. et al. (2006) Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. Blood 107, 1570-1581CrossRef Google Scholar PubMed

157Bourquin, J.P. et al. (2006) Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proceedings of the National Academy of Sciences of the United States of America 103, 3339-3344CrossRef Google Scholar PubMed

158Carroll, A. et al. (1991) The t(1;22) (p13;q13) is nonrandom and restricted to infants with acute megakaryoblastic leukemia: a Pediatric Oncology Group Study. Blood 78, 748-752CrossRef Google Scholar

159Bernstein, J. et al. (2000) Nineteen cases of the t(1;22)(p13;q13) acute megakaryblastic leukaemia of infants/children and a review of 39 cases: report from a t(1;22) study group. Leukemia 14, 216-218CrossRef Google Scholar

160Rubnitz, J.E. et al. (2007) Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia. Cancer 109, 157-163CrossRef Google Scholar PubMed

161Mercher, T. et al. (2001) Involvement of a human gene related to the Drosophila spen gene in the recurrent t(1;22) translocation of acute megakaryocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America 98, 5776-5779CrossRef Google Scholar

162Miralles, F. et al. (2003) Actin dynamics control SRF activity by regulation of its coactivator MAL. Cell 113, 329-342CrossRef Google Scholar PubMed

163Descot, A. et al. (2008) OTT-MAL is a deregulated activator of serum response factor-dependent gene expression. Molecular and Cellular Biology 28, 6171-6181CrossRef Google Scholar PubMed

164Ariyoshi, M. and Schwabe, J.W. (2003) A conserved structural motif reveals the essential transcriptional repression function of Spen proteins and their role in developmental signaling. Genes and Development 17, 1909-1920CrossRef Google Scholar PubMed

165Oswald, F. et al. (2002) SHARP is a novel component of the Notch/RBP-Jkappa signalling pathway. EMBO Journal 21, 5417-5426CrossRef Google Scholar PubMed

166Ma, X. et al. (2007) Rbm15 modulates notch-induced transcriptional activation and affects myeloid differentiation. Molecular and Cellular Biology 27, 3056-3064CrossRef Google Scholar PubMed

167Mercher, T. et al. (2009) The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knock-in mouse model. Journal of Clinical Investigation 119, 852-864Google Scholar

168Abdelhaleem, M. et al. (2007) High incidence of CALM-AF10 fusion and the identification of a novel fusion transcript in acute megakaryoblastic leukemia in children without Down's syndrome. Leukemia 21, 352-353CrossRef Google Scholar PubMed

169Oki, Y. et al. (2006) Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. Blood 107, 880-884CrossRef Google Scholar PubMed

Article contents

Normal and malignant megakaryopoiesis

Abstract

Access options

References

References

Further reading, resources and contacts

This article has been cited by the following publications. This list is generated based on data provided by Crossref.

Article contents

Normal and malignant megakaryopoiesis

Abstract

Access options

References

References

Further reading, resources and contacts

Save article to Kindle

Save article to Dropbox

Save article to Google Drive

Reply to: Submit a response

Your details

You have entered the maximum number of contributors

Conflicting interests